Related Experiment Video
Updated: Jan 12, 2026
07:30
Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
Published on: May 10, 2018
9.7K
A diet for dopaminergic neurons?
1Dipartimento di Medicina Sperimentale, Sezione di Fisiologia Umana G. Pagano, Università degli Studi di Palermo, Corso Tuköry 129, 90134 Palermo, Italy. g.digiovanni@unipa.it
Journal of Neural Transmission. Supplementum
|April 24, 2010
Summary
Parkinson's disease (PD) risk may be reduced by dietary factors. Adopting a healthy lifestyle, like the Mediterranean diet, shows promise in preventing dopamine neuron loss associated with PD.
Area of Science:
- Neuroscience
- Neurodegenerative Diseases
- Nutritional Science
Background:
- Parkinson's disease (PD) is the second leading neurodegenerative disorder.
- Dopamine (DA) neuronal cell loss in the substantia nigra is a hallmark of PD.
- Despite significant advances in understanding PD pathophysiology, no cure currently exists.
Purpose of the Study:
- To explore the role of dietary factors in counteracting dopamine degeneration in Parkinson's disease.
- To investigate the association between nutrient intake, specific foods, dietary patterns, and PD risk.
Main Methods:
- Review of existing animal studies on dietary factors and DA degeneration.
- Analysis of recent epidemiological studies linking dietary patterns to PD risk.
Main Results:
- Animal studies consistently highlight the importance of diet in preventing DA degeneration.
- Human studies show associations between dietary habits and the risk of developing PD.
- Specific nutrients, foods, and overall dietary patterns are linked to PD risk.
Conclusions:
- Dietary interventions and healthy lifestyle choices, such as the Mediterranean diet, may play a crucial role in reducing the risk of Parkinson's disease.
- Promoting a Mediterranean diet could be a key strategy for PD risk reduction.
Related Concept Videos
01:29Drugs Affecting Neurotransmitter Synthesis
2.1K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.1K
01:24Parkinson's Disease: Treatment
963
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
963
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
1.2K
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.2K
01:21Drugs Affecting Neurotransmitter Release or Uptake
1.5K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.5K
01:25Adrenergic Agonists: Indirect-Acting Agents
2.6K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
2.6K
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
799
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
799